NeuroOne Medical Technologies FY Conference Summary Company Overview - **Company**: NeuroOne Medical Technologies Corporation - **Ticker**: NasdaqCM: NMTC - **Technology**: Developed a thin film electrode platform technology for various neurological conditions including epilepsy, Parkinson's disease, back pain, and drug delivery for gene and cell therapies [3][4] Core Points and Arguments - **Device Portfolio**: - Four devices with FDA 510(k) clearance: three for brain-related applications and one for facial pain [4] - Key products include the OneRF Ablation System, which is the only FDA-cleared device for both diagnostic and therapeutic use [8][9] - The OneRF Trigeminal Nerve Ablation System targets trigeminal neuralgia, a condition with a high suicide rate among patients [10][11] - The spinal cord percutaneous paddle lead is designed for lower back pain, offering broader stimulation with less energy [12][13] - Basivertebral nerve ablation (BVNA) technology is in development, targeting lower back pain procedures [14][15] - Drug delivery technology capable of recording brain activity and stimulating tissue during therapy [16][17] - **Market Opportunity**: - Multi-billion dollar market potential for all devices, with spinal cord stimulation generating $3-4 billion in revenue [6] - Epilepsy, drug delivery, and basivertebral nerve ablation are expected to grow into billion-dollar businesses [6] - **Partnerships**: - Current partnerships with Mayo Clinic and Zimmer Biomet, with potential for additional collaborations [4][5] - Received $8.5 million in licensing fees from Zimmer Biomet for exclusive distribution rights [5] - **Financial Overview**: - Cash on hand as of December 31: $3.6 million, with accounts receivable of $2.7 million [20] - Product revenue for the fiscal first quarter: $2.9 million, a 5.5% sequential increase [20] - Expected product revenue for the year: at least $10.5 million, a minimum of 17% increase over the prior year [21] - **Upcoming Catalysts**: - Continued revenue growth for the RF brain ablation system [23] - Full launch of trigeminal nerve ablation system expected next quarter [23] - Potential licensing agreements and commercialization for drug delivery [23] Additional Important Content - **Regulatory Path**: - Preparing for ISO 13485 certification to facilitate international distribution [6][21] - The regulatory path for BVNA is expected to be a 510(k) [15] - **Safety and Efficacy**: - No reported adverse events in epilepsy procedures using the OneRF system, with many patients experiencing significant seizure reduction [9][28] - A registry has been established to collect data on patient outcomes, which is critical for expanding device utilization [27][29] - **Leadership Experience**: - Team includes professionals with experience from major medical device companies, enhancing credibility and expertise [18] - **Future Outlook**: - Strong potential for partnerships in 2026, with ongoing discussions for various technologies [32] This summary encapsulates the key aspects of NeuroOne Medical Technologies as discussed in the conference, highlighting its innovative technology, market potential, financial health, and strategic direction.